GlassScriptPhysician profile
Bruce M Stark
NPI 1902801301
$8,516.43
in general payments reported to CMS, 2019-2025
56 companies · $957 in 2025
The $957 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $1,001 · 2021: $1,264 · 2022: $2,460 · 2023: $1,262 · 2024: $528 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,426.48 | 2022 | |
| Amgen INC. | $615.99 | 2019-2023 | Otezla, Repatha |
| Abbvie INC. | $473.64 | 2021-2025 | Vraylar, Qulipta |
| Merck Sharp & Dohme LLC | $393.29 | 2021-2023 | Belsomra, Verquvo, Steglatro |
| Optinose US, INC. | $386.69 | 2019-2025 | |
| Esperion Therapeutics, INC. | $351.65 | 2021-2023 | Nexletol, Nexlizet |
| Allergan, INC. | $345.97 | 2019-2020 | |
| Gilead Sciences, INC. | $329.28 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $295.22 | 2019-2023 | Ztlido |
| Kowa Pharmaceuticals America, INC. | $267.82 | 2020-2023 | Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.79 | 2019-2025 | Relistor, Xifaxan |
| Almatica Pharma LLC | $230.95 | 2020-2023 | Loreev Xr, Gralise |
| Lilly USA, LLC | $176.27 | 2019-2024 | Zepbound, Jardiance |
| Indivior INC. | $173.38 | 2019-2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $163.30 | 2022-2023 | Quviviq |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.